- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05201352
Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine (TASKIN)
Multicentric Randomized Phase I/II Study to Evaluate Efficacy of Trifluridine/Tipiracil Plus XB2001 (Anti-IL-1α True Human Antibody) Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine
Unresectable metastatic colorectal cancer (mCRC) remains an incurable disease. After failure of conventional treatments involving fluoropyrimidines, oxaliplatin and irinotecan in combination or not with biotherapies targeting EGFR and VEGF; regorafenib shows a modest improvement in overall survival. Recently, trifluridine/tipiracil has also shown efficacy in phase 3 with an overall survival of around 7 months. Trifluridine/tipiracil has become the standard of care for advanced mCRC in most western countries. However, the objective response rate remains very low and the survival gain remains moderate (+2 months). Therefore, new strategies are needed to ensure that mCRC patients who have received multiple lines of therapy can receive more effective treatments.
Based on previous clinical trials on IL-1 inhibition and our preclinical data, IL-1 inhibition may increase the efficacy of trifluridine/tipiracil. The goal is to test whether the addition of XB2001 to trifluridine/tipiracil could be synergistic.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This project proposes to evaluate trifluridine/tipiracil plus XB2001 in patients with metastatic colorectal cancer previously treated with oxaliplatin, fluoropyrimidine and irinotecan in combination or not with an anti-angiogenic and an anti-EGFR for RAS Wild type tumor.
The project will consist of a randomized (1:1 ratio), double-blind, non-comparative, multi-center Phase II study with two treatment arms:
- Experimental arm: trifluridine/tipiracil + XB2001
- Control arm: trifluridine/tipiracil + placebo
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: François GHIRINGHELLI, PU-PH
- Phone Number: 03.80.73.77.14
- Email: fghiringhelli@cgfl.fr
Study Locations
-
-
-
Angers, France, 49055
- Not yet recruiting
- ICO Angers
-
Contact:
- Victor SIMMET, Dr
- Phone Number: +33 02 41 35 27 00
- Email: victor.simmet@ico.unicancer.fr
-
Avignon, France, 84000
- Not yet recruiting
- Institut Sainte Catherine
-
Contact:
- Laurent MINEUR, Dr
- Phone Number: +33 04 90 27 61 81
- Email: l.mineur@isc84.org
-
Besançon, France, 25000
- Not yet recruiting
- CHU Jean Minjoz
-
Contact:
- Christophe BORG, Pr
- Phone Number: +33 03 70 63 24 03
- Email: xtoph.borg@gmail.com
-
Bordeaux, France, 33000
- Not yet recruiting
- Institut Bergonie
-
Contact:
- Simon PERNOT, Dr
- Phone Number: +33 06 81 07 82 05
- Email: simon.pernot@gmail.com
-
Carcassonne, France, 11810
- Not yet recruiting
- Centre Hospitalier Carcassonne
-
Contact:
- Jean-Luc LABOUREY, Dr
- Phone Number: +33 04 68 24 33 35
- Email: Jean-luc.labourey@ch-carcassonne.fr
-
Clermont-Ferrand, France, 63003
- Not yet recruiting
- CHU Estaing
-
Contact:
- Marine JARY, Dr
- Phone Number: +33 04 73 75 05 08
- Email: mjary@chu-clermontferrand.fr
-
Levallois-Perret, France, 92300
- Not yet recruiting
- Hopital Franco-Britannique
-
Contact:
- Benoist CHIBAUDEL, Dr
- Phone Number: +33 01 47 59 59 65
- Email: benoist.chibaudel@ihfb.org
-
Limoges, France, 87000
- Not yet recruiting
- CHU Dupuytren
-
Contact:
- Frédéric THUILLIER, Dr
- Phone Number: +33 05 55 05 63 96
- Email: frederic.thuillier@chu-limoges.fr
-
Nantes, France, 44000
- Not yet recruiting
- CHU Nantes
-
Contact:
- Yann TOUCHEFEU, Pr
- Phone Number: +33 02 40 08 31 52
- Email: yann.touchefeu@chu-nantes.fr
-
Plérin, France, 22190
- Not yet recruiting
- Cario-Hpca
-
Contact:
- Jérôme MARTIN-BABAU, Dr
- Phone Number: +33 02 96 75 22 16
- Email: j.martin@cario-sante.fr
-
Reims, France, 51100
- Not yet recruiting
- Institut Jean Godinot
-
Contact:
- Damien BOTSEN, Dr
- Phone Number: +33 03 26 50 44 38
- Email: damien.botsen@reims.unicancer.fr
-
Saint Herblain, France, 44805
- Not yet recruiting
- Institut de Cancérologie de l'Ouest
-
Contact:
- Hélène SENELLART, Dr
- Phone Number: +33 02 40 67 99 00
- Email: helene.senellart@ico.unicancer.fr
-
-
Bourgogne
-
Dijon, Bourgogne, France, 21000
- Recruiting
- CHU Dijon
-
Contact:
- Côme Lepage, Pr
- Phone Number: +33 03 80 29 37 50
- Email: come.lepage@u-bourgogne.fr
-
Dijon, Bourgogne, France, 21000
- Recruiting
- Centre Georges-Francois Leclerc
-
Contact:
- François GHIRINGHELLI, Pr
- Phone Number: +33 03 80 73 75 00
- Email: fghiringhelli@cgfl.fr
-
Contact:
- Emilie Rederstorff
- Phone Number: +33 03 34 45 81 16
- Email: erederstorff@cgfl.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female that must have signed a written informed consent prior to any study specific procedures
- Aged ≥ 18 years at randomization
- Patient with histologically proven metastatic colorectal cancer previously treated for metastatic disease by chemotherapy treatment including oxaliplatin, irinotecan, fluoropyrimidine, antiangiogenic (anti-VEGF: bevacizumab or aflibercept) and anti-EGFR (cetuximab or panitumumab) if indicated (MSI tumor could be included if previously pretreated with anti PD1/PDL1 therapy)
- Have a performance status of 0 or 1 according to the WHO Easter Cooperative Oncology Group (ECOG)
- Knowledge of RAS, BRAF, Microsatellite status
- Baseline tumoral evaluation (thoraco-abdomino-pelvic computed tomography) perfromed within 21 days before randomization with at least one measurable lesion according to RECIST 1.1 criteria.
- Patient willing and able to comply with protocol for the duration of the study including: scheduled visits and exams, visits during the follow-up and treatment compliance.
- Adequat hepatic, renal and bone marrow function within the following limits:
- Total bilirubin ≤ 1,5 times the upper limit of normal (ULN) (unless documented Gilbert's syndrome);
- ASAT et ALAT ≤ 5 times ULN;
- Measured Creatinine clearance (Cockcroft and Gault) > 30 ml / min
- Absolute Neutrophil Count (ANC) > 1,5. 109 / L;
- Platelet count ≥ 150. 109 / L;
- Haemoglobin ≥ 9 g / dL (patients can be included even if they have been transfused)
- Albuminemia ≥ 30 g / L;
- Negative Hepatitis B, C and HIV serologies, or absence of active B or C hepatitis
- Urea protein, urine dipstick should be less than 2 crossese or <1g/kg
- Availability of tumor material dated less than 2 years with sufficient quantity (15 to 20 whithe slides)
- Patient must be affiliated to a social health insurance
- Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients (urine within 72h or serum pregnancy within 14 days prior to inclusion).
- Women of childbearing potential willing to use adequate contraception method (including the use of a mechanical method of contraception in the event of hormonal contraceptive treatment) during the treatment period and 6 months following the end of treatment.
- Male patients with a partner of childbearing potential should use effective contraception during treatment and for up to 6 months after stopping treatment.
- Normal ECG or ECG without clinically significant findings with QTc < 470 ms.
Exclusion Criteria:
- Other concurrent malignancies the last 3 years, except adequately treated cone-biopsied in situ carcinoma of the cervix, basal cell, squamous cell carcinoma of the skin or low risk prostate cancer. Patient who have had potentially curative therapy for a prior malignancy are eligible provided there has been no evidence of disease for ≥ 5 years and the risk of recurrence is considered low.
- Symptomatic brain metastases
- Estimated prognosis <3 months.
- Mutational status BRAF mutant
- Participation in progress, or in the 30 days preceding the first scheduled day of dosing in this study, in another therapeutic trial with an experimental molecule or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer.
- Severe unbalanced illness, underlying infection that may prevent the patient from receiving treatment. Patients with a clinically important and unresolved Grade 3 or 4 non-haematologic adverse reaction related to previous therapies. Also participant with any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment.
- Bowel obstruction or sub-obstruction or a history of inflammatory bowel disease or significant gasto intestinal disorder
- History of autoimmune or inflammatory disease or interstitial lung disease.
- Patient with congenital galactosemia, total lactase deficiency (lactose intolerance) or glucose-galactose malabsorption syndrome
- Severe arterial thromboembolic events less than 6 months before randomization
- New York Heart Association (NYHA) Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure (defined as ≥ 160/100 mm Hg)
- Clinically significant decrease in performance status (medical records) within 2 weeks of intended first dose administration.
- -Contraindication to receive a treatment with trifluridine/tipiracil or an anti-IL-1α (XB2001 True Human antibody)
- Concomitant systemic treatment with immunotherapy, immunosuppressants, corticosteroid therapy ≥ 10 mg equivalent prednisone/prednisolone or hormone therapy: corticosteroid therapy administered chronically, immunosuppressive treatment, biotherapy administered as part of the management of an inflammatory disease (anti-TNF, anti-IL6, anti-IL1, anti PD-1, anti EGFR etc.) and live virus vaccines administered up to 14 days prior the first scheduled dose of treatement administration.
- Current pregnancy (mandatory pregnancy test at baseline for female of childbearing potential) or breastfeeding.
- Patient with any psychiatric, psychological, sociological, geographical problem or other severe concomitant disease, disorder or condition that potentially compromising the understanding of the information, the safety of the patient, the interpretation of study results or the conduct of the study compliance with the study protocol and follow-up schedule.
- Patient deprived of their liberty or under guardianship, curatorship or safeguard of justice.
- Known or suspected history of immunosuppression, including history of invasive opportunistic infections (e.g tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution. Presence or suspicion of active bacterial, fungal or viral infections, or uncontrolled fever.
- Major surgery within 2 weeks prior to randomization or have an unhealed operation wounds.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental arm
trifluridine/tipiracil + XB2001
|
trifluridine/tipiracil every 28 days + XB2001 1000mg intravenous infusion every 2 weeks
|
Placebo Comparator: Control arm
trifluridine/tipiracil + placebo
|
trifluridine/tipiracil every 28 days + Placebo intravenous infusion every 2 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum Tolerated Dose (MTD) of XB2001
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
At the end of Cycle 1 (each cycle is 28 days)
|
Overall survival
Time Frame: 6-month
|
6-month
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Antimetabolites
- Trifluridine
Other Study ID Numbers
- 2020-004601-31
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Lung | Resectable Colorectal CarcinomaUnited States
Clinical Trials on trifluridine/tipiracil + XB2001
-
UNICANCERActive, not recruitingMetastatic Colorectal CancerFrance, Belgium
-
Roswell Park Cancer InstitutePfizerRecruitingAdvanced Malignant Solid Neoplasm | Metastatic Colorectal Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Clinical Stage III... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Colorectal Carcinoma | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedCholangiocarcinoma | Stage III Gallbladder Cancer AJCC v7 | Stage IIIA Gallbladder Cancer AJCC v7 | Stage IIIB Gallbladder Cancer AJCC v7 | Stage IV Gallbladder Cancer AJCC v7 | Stage IVA Gallbladder Cancer AJCC v7 | Stage IVB Gallbladder Cancer AJCC v7United States
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)Active, not recruitingRecurrent Colon Carcinoma | Metastatic Colorectal Carcinoma | Stage IV Colon Cancer AJCC v7 | Stage IVA Colon Cancer AJCC v7 | Stage IVB Colon Cancer AJCC v7 | Refractory Colorectal CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Mayo ClinicNational Comprehensive Cancer NetworkCompletedStage III Gallbladder Cancer AJCC v8 | Stage IIIA Gallbladder Cancer AJCC v8 | Stage IIIB Gallbladder Cancer AJCC v8 | Refractory Gallbladder Carcinoma | Stage IV Gallbladder Cancer AJCC v8 | Stage IV Distal Bile Duct Cancer AJCC v8 | Stage IV Intrahepatic Bile Duct Cancer AJCC v8 | Stage IVB Gallbladder... and other conditionsUnited States
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Colorectal CancerTurkey, Poland, Brazil, France, Ireland, Italy, Portugal, Romania, Ukraine, Bulgaria, Australia, Belgium, Croatia, Panama, Slovakia, Slovenia
-
AHS Cancer Control AlbertaTom Baker Cancer CentreWithdrawnMetastatic Triple Negative Breast CancerCanada